0.01Open0.01Pre Close0 Volume6.18K Open Interest5.00Strike Price0.00Turnover135.58%IV62.14%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0357Delta0.1021Gamma309.00Leverage Ratio-0.0023Theta0.0000Rho11.03Eff Leverage0.0004Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet